Skip to main content

21 September 2022

WuXi Advanced Therapies: Company Profile

OXGENE

Sponsored/European Biopharmaceutical Review /21 September 2022

Download PDF – 432.6 KB

Abstract

Advanced Technologies, Manufacturing, and Testing Solutions for Cell and Gene Therapy Innovators

WuXi Advanced Therapies (WuXi ATU), the advanced therapies business unit of WuXi AppTec, is a Contract Testing, Development, and Manufacturing Organisation (CTDMO) that offers integrated platforms to transform the discovery, development, testing, GMP manufacture, and commercialisation of cell and gene therapies. Together with OXGENE, a WuXi Advanced Therapies Company, we offer complete end-to-end solutions to enable pioneering companies to deliver breakthrough therapies to patients.

Download the resource to continue reading.
×